Kim Brøsen
Kim Brøsen
Professor in Clinical Pharmacology, University of Southern Denmark
Email confirmado em - Página inicial
Citado por
Citado por
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms
SH Sindrup, LF Gram, K Brøsen, O Eshøj, EF Mogensen
Pain 42 (2), 135-144, 1990
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages
J Kirchheiner, K Brøsen, ML Dahl, LF Gram, S Kasper, I Roots, F Sjöqvist, ...
Acta Psychiatrica Scandinavica 104 (3), 173-192, 2001
Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
Danish University Antidepressant Group
Journal of Affective Disorders 18 (4), 289-299, 1990
The hypoalgesic effect of tramadol in relation to CYP2D6
L Poulsen, L Arendt‐Nielsen, K Brøsen, SH Sindrup
Clinical Pharmacology & Therapeutics 60 (6), 636-644, 1996
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial
SH Sindrup, G Andersen, C Madsen, T Smith, K Brøsen, TS Jensen
Pain 83 (1), 85-90, 1999
Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention
J Hallas, B Harvald, LF Gram, E Grodum, K Brøsen, T Haghfelt, N Damsbo
Journal of internal medicine 228 (2), 83-90, 1990
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
K Brøsen, E Skjelbo, BB Rasmussen, HE Poulsen, S Loft
Biochemical pharmacology 45 (6), 1211-1214, 1993
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
U Jeppesen, LF Gram, K Vistisen, S Loft, HE Poulsen, K Brøsen
European journal of clinical pharmacology 51, 73-78, 1996
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy
SH Sindrup, U Bjerre, A Dejgaard, K Brøsen, T Aaes‐Jørgensen, LF Gram
Clinical Pharmacology & Therapeutics 52 (5), 547-552, 1992
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
K Brøsen, LF Gram
European Journal of Clinical Pharmacology 36, 537-547, 1989
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects
L Poulsen, K Brøsen, L Arendt-Nielsen, LF Gram, K Elbaek, SH Sindrup
European journal of clinical pharmacology 51, 289-295, 1996
Drug related admissions to medical wards: a population based survey.
J Hallas, LF Gram, E Grodum, N Damsbo, K Brosen, T Haghfelt, B Harvald, ...
British journal of clinical pharmacology 33 (1), 61-68, 1992
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
MMH Christensen, C Brasch-Andersen, H Green, F Nielsen, P Damkier, ...
Pharmacogenetics and genomics 21 (12), 837-850, 2011
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors
BB Rasmussen, TH Brix, KO Kyvik, K Brøsen
Pharmacogenetics and Genomics 12 (6), 473-478, 2002
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
SH Sindrup, K Brøsen, MGJ Hansen, T Aaes-Jørgensen, KF Overø, ...
Therapeutic drug monitoring 15 (1), 11-17, 1993
The relationship between paroxetine and the sparteine oxidation polymorphism
SH Sindrup, K Brøsen, LF Gram, J Hallas, E Skjelbo, A Allen, GD Allen, ...
Clinical Pharmacology & Therapeutics 51 (3), 278-287, 1992
The pharmacogenetics of codeine hypoalgesia
SH Sindrup, K Brøsen
Pharmacogenetics and Genomics 5 (6), 335-346, 1995
Recent developments in hepatic drug oxidation implications for clinical pharmacokinetics
K Brosen
Clinical pharmacokinetics 18, 220-239, 1990
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
K Brøsen, JG Hansen, KK Nielsen, SH Sindrup, LF Gram
European journal of clinical pharmacology 44, 349-355, 1993
Inhibitors of imipramine metabolism by human liver microsomes.
E Skjelbo, K Brosen
British journal of clinical pharmacology 34 (3), 256-261, 1992
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20